PP
PRME icon

PDT Partners’s Prime Medicine PRME Stock Holding History

PDT Partners’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-49,325
Closed -$254K – 801
2024
Q2 		$254K Buy
+49,325
New +$299K 0.02% 581

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PDT Partners's PRME Position: Q3 2024 in Review

PDT Partners sold out of Prime Medicine (PRME) in Q3 2024, closing a stake of 49,325 shares — an estimated $254K sold.

PDT Partners first reported a position in PRME in Q2 2024 and held it in 1 quarter. The position peaked at $254K in Q2 2024. 116 funds tracked by Wall St. Rank hold PRME as of Q3 2024.

  • PDT Partners reported no remaining Prime Medicine position as of Q3 2024 after selling out during the quarter.
  • PDT Partners sold 49,325 Prime Medicine shares in Q3 2024, an estimated $254K.
  • PDT Partners first reported a position in Prime Medicine in Q2 2024 and held it in 1 quarter.
  • PDT Partners's Prime Medicine position peaked at $254K in Q2 2024.
  • 116 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2024.

Based on PDT Partners's 13F filing for Q3 2024, filed 14 Nov 2024.